Details of the Drug Pharmacogenomic Perturbation Atlas

Cyclopentolate Drug Info

Ciclopentolato; Cyclopentoiate; Cyclopentolatum; Cyclopentylate; Cylate; Diopentolate; Mydrilate; Bell Pentolate; Minims Cyclopentolate; Bell Pentolate (TN); Ciclopentolato [INN-Spanish]; Cyclopentolate (INN); Cyclopentolate [INN:BAN]; Cyclopentolatum [INN-Latin]; Ocu-Pentolate; B-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; Beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; Alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; (+-)-cyclopentolate; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester

Therapeutic Class

Parasympatholytics

Cross-matching ID

PubChem CID

2905

ChEBI ID

CHEMBL4024

CAS Number

CAS 512-15-2

TTD Drug ID

D0B1EV

General Information of Drug (ID: DMA8LM5)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.04	0.00e+0	34/36 (94.44%)	POLD2;FEN1;MCM5;...
Homologous recombination	1.86	1.53e-2	35/41 (85.37%)	POLD2;BARD1;BRCA1;...
Butanoate metabolism	1.82	1.79e-2	23/28 (82.14%)	HMGCS1;ACAT2;ALDH5A1;...
PPAR signaling pathway	1.77	2.49e-2	66/74 (89.19%)	HMGCS1;PCK1;SLC27A2;...
Base excision repair	1.77	1.99e-2	29/33 (87.88%)	OGG1;POLD2;NEIL3;...
Phenylalanine metabolism	1.76	1.92e-2	14/17 (82.35%)	ALDH3B1;PAH;MAOB;...
Fanconi anemia pathway	1.74	1.86e-2	36/54 (66.67%)	BRCA1;TOP3A;RPA3;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.80	4.11e-2	62/70 (88.57%)	MAPK8;TJP1;MAPK9;...
Amoebiasis	-1.81	4.22e-2	99/102 (97.06%)	ACTN4;CD1A;CD1C;...
Measles	-1.83	2.93e-2	133/139 (95.68%)	MAP3K7;JAK1;STAT2;...
IL-17 signaling pathway	-1.88	1.56e-2	84/94 (89.36%)	HSP90B1;CSF3;HSP90AA1;...
Viral protein interaction with cytokine and cytokine re...	-1.92	1.76e-2	84/100 (84%)	CCR5;IL18R1;LTA;...
TNF signaling pathway	-1.97	2.35e-2	103/112 (91.96%)	VCAM1;TNFAIP3;RPS6KA4;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H